KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Cash & Equivalents (2016 - 2026)

Quest Diagnostics' Cash & Equivalents history spans 18 years, with the latest figure at $393.0 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 109.04% to $393.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $393.0 million, a 109.04% increase, with the full-year FY2025 number at $420.0 million, down 23.5% from a year prior.
  • Cash & Equivalents hit $393.0 million in Q1 2026 for Quest Diagnostics, down from $420.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for DGX hit a ceiling of $790.0 million in Q2 2022 and a floor of $126.0 million in Q2 2023.
  • Historically, Cash & Equivalents has averaged $438.6 million across 5 years, with a median of $420.0 million in 2025.
  • Biggest five-year swings in Cash & Equivalents: plummeted 84.05% in 2023 and later soared 434.27% in 2024.
  • Tracing DGX's Cash & Equivalents over 5 years: stood at $315.0 million in 2022, then surged by 117.78% to $686.0 million in 2023, then fell by 19.97% to $549.0 million in 2024, then decreased by 23.5% to $420.0 million in 2025, then dropped by 6.43% to $393.0 million in 2026.
  • Business Quant data shows Cash & Equivalents for DGX at $393.0 million in Q1 2026, $420.0 million in Q4 2025, and $432.0 million in Q3 2025.